Better treatments for acute myeloid leukemia sought with largest dataset
Researchers have put together the largest dataset of acute myeloid leukemia, featuring 672 samples from 562 patients. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 17, 2018 Category: Consumer Health News Source Type: news

AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which sho... Biopharmaceuticals, Oncology, FDA AbbVie, IMBRUVICA, ibrutinib, obinutuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 17, 2018 Category: Pharmaceuticals Source Type: news

Vast leukemia dataset could help researchers match therapies to patients
(Howard Hughes Medical Institute) Data on the molecular makeup and drug sensitivity of hundreds of patient samples could accelerate progress against the aggressive blood cancer acute myeloid leukemia. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

OHSU-led effort results in largest cancer dataset of its kind
(Oregon Health& Science University) After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, 'Functional Genomic Landscape of Acute Myeloid Leukemia,' published today in Nature. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 17, 2018 Category: Cancer & Oncology Source Type: news

Nurse, 22, lands a job at the same hospital where she was treated for leukaemia
Brooke Evans, from Redditch in Worcestershire, has started work as a haematology nurse at Queen's Hospital in Birmingham, where she had chemo in 2013. (Source: the Mail online | Health)
Source: the Mail online | Health - October 16, 2018 Category: Consumer Health News Source Type: news

Biased antagonism of CXCR4 avoids antagonist tolerance
Repeated dosing of drugs targeting G protein–coupled receptors can stimulate antagonist tolerance, which reduces their efficacy; thus, strategies to avoid tolerance are needed. The efficacy of AMD3100, a competitive antagonist of the chemokine receptor CXCR4 that mobilizes leukemic blasts from the bone marrow into the blood to sensitize them to chemotherapy, is reduced after prolonged treatment. Tolerance to AMD3100 increases the abundance of CXCR4 on the surface of leukemic blasts, which promotes their rehoming to the bone marrow. AMD3100 inhibits both G protein signaling by CXCR4 and β-arrestin1/2–depend...
Source: Signal Transduction Knowledge Environment - October 16, 2018 Category: Science Authors: Hitchinson, B., Eby, J. M., Gao, X., Guite-Vinet, F., Ziarek, J. J., Abdelkarim, H., Lee, Y., Okamoto, Y., Shikano, S., Majetschak, M., Heveker, N., Volkman, B. F., Tarasova, N. I., Gaponenko, V. Tags: STKE Research Articles Source Type: news

Delving Where Few Others Have Gone, Leukemia Researchers Open New Path
A Wilmot Cancer Institute study uncovers how a single gene could be at fault in acute myeloid leukemia (AML), one of the deadliest cancers. The breakthrough gives researchers renewed hope that a gene-targeted therapy could improve AML survival rates, which have not budged in recent years. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - October 15, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
Duvelisib extended progression - free survival to 13.3 months versus 9.9 months for ofatumumab (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 10, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Journal, Source Type: news

Duvelisib Promising for Chronic Lymphocytic Leukemia, SLL
WEDNESDAY, Oct. 10, 2018 -- For patients with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the oral, dual inhibitor of phosphoinositide 3-kinase- δ and -γ, duvelisib, seems effective, according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2018 Category: Pharmaceuticals Source Type: news

Breast cancer drug may also work against form of leukemia
A new drug used for advanced breast cancer can also work effectively to treat acute myeloid leukemia, according to a study with mice and cells in a lab. (Source: Health News - UPI.com)
Source: Health News - UPI.com - October 9, 2018 Category: Consumer Health News Source Type: news

CAR T-Cell Therapy for Pediatric Leukemia Is Cost-effective CAR T-Cell Therapy for Pediatric Leukemia Is Cost-effective
A new analysis shows that, despite its exorbitant price tag, the CAR T-cell therapy tisagenlecleucel for pediatric leukemia appears to be cost-effective.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 9, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

CAR T-Cell Therapy Cost-Effective in Pediatric Leukemia
(MedPage Today) -- But long-term outcomes key; report follows NICE thumbs-down in adult DLBCL (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 8, 2018 Category: American Health Source Type: news

Breast cancer drug could be used to treat life-threatening leukaemia
(Newcastle University) A recently-approved breast cancer drug could be used to target and treat a life-threatening leukaemia, new research has revealed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 8, 2018 Category: Cancer & Oncology Source Type: news

How Scientists Are Treating Breast Cancer Using the Immune System
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had meta...
Source: TIME: Health - October 4, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized breast cancer news Frontiers of Medicine Source Type: news

How Scientists Are Treating Breast Cancer Using the Immune System
As a pharmacist, Kathy James considers herself well educated about the importance of getting regular cancer screenings. Even though the 55-year-old had no history of cancer in her family, she never skipped her regular mammograms, and she gave herself regular breast exams. So she was dumbfounded when, during one of those self-exams in May 2017, she felt a marble-size lump in her left breast. A visit to the doctor confirmed it. “The radiologist came in with his hands in his pockets and looked down and said, ‘It doesn’t look good,'” James says. After a biopsy, James and her husband learned she had meta...
Source: TIME: Science - October 4, 2018 Category: Science Authors: Alice Park Tags: Uncategorized breast cancer news Frontiers of Medicine Source Type: news

Duvelisib has marked response, survival benefit in difficult-to-treat leukemia and lymphoma
(American Society of Hematology) For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease outcomes, according to phase III trial data published today in the journal Blood. The DUO trial studied duvelisib versus ofatumumab, an approved standard-of-care chemotherapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). According to the study, duvelisib extended PFS from a median of 9.9 months on ofatumumab to 13.3 months. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

MD Anderson and Cyclacel Pharmaceuticals announce strategic alliance to study novel Cyclacel medicin
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center and Cyclacel Pharmaceuticals, Inc., today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and other advanced leukemias. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 4, 2018 Category: Cancer & Oncology Source Type: news

Risk of Relapse Up for Teens, Young Adults With Leukemia
Increased risk of on - therapy relapse, relapse after completing therapy versus children with ALL (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 1, 2018 Category: Cancer & Oncology Tags: Oncology, Pathology, Pediatrics, Journal, Source Type: news

Rare manufacturing glitch raises concern over CAR-T therapies: study
A single leukemia cell inadvertently got mixed in with a batch of a patient's immune cells that were being manufactured into a CAR-T cell therapy and it acquired resistance to the treatment with deadly results, University of Pennsylvania researchers reported on Monday. (Source: Reuters: Health)
Source: Reuters: Health - October 1, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Breakthrough Leukemia Treatment Backfires in a Rare Case
The groundbreaking treatment that genetically engineers a patient ’ s own cells to fight leukemia turned lethal in one patient, reversing his remission. (Source: NYT Health)
Source: NYT Health - October 1, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Leukemia Immune System Immunotherapy Genetic Engineering Cancer Children's Hospital of Philadelphia University of Pennsylvania Novartis AG Whitehead, Emma Kymriah Drugs (Pharmaceuticals) Nature Medicine Marco Ruella Source Type: news

CAR T-Cell Therapy May ‘ Change the Paradigm of Treating Mesothelioma ’
Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. “I think this is going to change the paradigm of treating mesotheliom...
Source: Asbestos and Mesothelioma News - October 1, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Leukaemia cells can decrease insulin activity in healthy cells
Research, published inCancer Cell, has shown that leukaemia cells can lower insulin sensitivity in healthy cells and decrease insulin production in the body, to benefit leukaemia growth.News Medical (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 1, 2018 Category: Endocrinology Source Type: news

FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukemia or multiple myeloma
(Source: Food and Drug Administration)
Source: Food and Drug Administration - September 28, 2018 Category: American Health Source Type: news

Intermittent fasting inhibits the most common type of childhood leukemia
(Natural News) Intermittent fasting is all the rage right now; it’s been credited with a host of health benefits and heralded as the next big thing in weight loss. The more intermittent fasting (IF) is studied, the more impressive it seems to become: Recent research has shown that fasting regularly, as one does with IF,... (Source: NaturalNews.com)
Source: NaturalNews.com - September 26, 2018 Category: Consumer Health News Source Type: news

Boy, 9, who beat leukemia meets the doctor who saved his life by donating his bone marrow
Johnny Sawyer Dyer, nine, of Corryton, Tennessee, finally met the bone marrow donor who save his life, Kevin Schwartzel, 29, a physician assistant from San Diego, California, on Saturday. (Source: the Mail online | Health)
Source: the Mail online | Health - September 26, 2018 Category: Consumer Health News Source Type: news

Duvelisib Approved for Certain Lymphomas Duvelisib Approved for Certain Lymphomas
The FDA approved the new drug for use in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and follicular lymphoma.FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 25, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

BLINCYTO ® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia
First Approved Oncology Treatment From Amgen Astellas Joint Venture BLINCYTO is the First-and-Only Approved CD19-Directed CD3 Bispecific T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., Sept. 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO® (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen and Astellas Pharma Inc., a pharmaceuti...
Source: Amgen News Release - September 25, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

9-year-old boy who had leukemia surprised with meeting bone marrow donor
In a heartwarming reunion, a 9-year-old celebrating his cancer remission has met the man who saved him. (Source: ABC News: Health)
Source: ABC News: Health - September 24, 2018 Category: Consumer Health News Tags: GMA Source Type: news

FDA Approves Copiktra (duvelisib) Capsules for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
BOSTON--(BUSINESS WIRE)--Sep. 24, 2018-- Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 24, 2018 Category: Drugs & Pharmacology Source Type: news

Roche announces CHMP recommendation for EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of people with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - September 21, 2018 Category: Pharmaceuticals Source Type: news

FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Second Orphan Drug Designation for OBI-3424, a novel first-in-class targeted therapy for solid and liquid tumors that express aldo-keto reductase 1c3 (AKR1C3) enzyme TAIPEI, Taiwan, Sept. 19, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma... Biopharmaceuticals, Oncology, FDA OBI Pharma, Acute Lymphoblastic Leukemia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 19, 2018 Category: Pharmaceuticals Source Type: news

Critically Elevated Potassium in Chronic Lymphocytic Leukemia Critically Elevated Potassium in Chronic Lymphocytic Leukemia
A misdiagnosis as to the cause of hyperkalemia in this patient led to unnecessary dialysis, demonstrating the need to be alert to potentially false potassium results in patients with elevated WBC counts.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 19, 2018 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Decades later, man meets the UCLA doctor who saved his life
It ’s 1970 and 10-month-old Maurice Elias lay in a hospital bed in the pediatric intensive care unit dangerously malnourished, at just 14 pounds, and with a severe infection in his mouth. The antibiotics that doctors at UCLA had been using to treat Maurice, who had been born without a functional immu ne system, were no longer working.The only way Maurice was going to survive was a bone marrow transplant.“If we couldn't find a way to give Maurice a working immune system, he was going to die. And the only way to do so was with a risky transplant that could be fatal, too,” said Dr. Richard Stiehm, the UCLA d...
Source: UCLA Newsroom: Health Sciences - September 19, 2018 Category: Universities & Medical Training Source Type: news

Medical News Today: Leukemia rash pictures
Leukemia is a type of cancer that affects white blood cells. Symptoms may include petechiae, which are tiny red, brown, or purple spots on the skin that resemble a rash. Rashes and other skin conditions are common and are not usually signs of cancer. Learn what a leukemia rash looks like and when to see a doctor here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 17, 2018 Category: Consumer Health News Tags: Leukemia Source Type: news

More toxic to humans than high fructose corn syrup, this dirty little secret ingredient is COMMON in U.S. foods (and beverages)
(Natural News) Ever wonder why one third of all Americans get cancer at some point in their lifetime, even though hardly anyone got it a century ago? How about leukemia, do you think it’s hereditary? You would be dead wrong. A common ingredient in soft drinks and most jarred peppers and pickles causes leukemia, but... (Source: NaturalNews.com)
Source: NaturalNews.com - September 15, 2018 Category: Consumer Health News Source Type: news

FDA Approves Novel Treatment for Hairy Cell Leukemia
Lumoxiti, a CD22 - directed cytotoxin, approved for adults who have had at least two prior therapies (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news

FDA Approves Novel Treatment for Hairy Cell Leukemia
FRIDAY, Sept. 14, 2018 -- Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2018 Category: Pharmaceuticals Source Type: news

Novel Treatment Approved for 'Hairy Cell' Leukemia
Title: Novel Treatment Approved for 'Hairy Cell' LeukemiaCategory: Health NewsCreated: 9/13/2018 12:00:00 AMLast Editorial Review: 9/14/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 14, 2018 Category: Cancer & Oncology Source Type: news

Children who develop ALL may have dysregulated immune function at birth
(American Association for Cancer Research) Neonatal concentrations of eight detectable inflammatory markers were significantly different in children later diagnosed with B-cell precursor acute lymphoblastic leukemia (ALL) compared with controls. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 14, 2018 Category: Cancer & Oncology Source Type: news

Novel Treatment Approved for ‘ Hairy Cell ’ Leukemia
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 13, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, FDA Approvals, Source Type: news

FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia
Moxetumomab pasudotox is a CD22-directed cytotoxin or immunotoxin and is a first-in-class type of treatment for patients with HCLFDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia
September 13, 2018 -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 13, 2018 Category: Drugs & Pharmacology Source Type: news

Lumoxiti OK'd for Hairy Cell Leukemia
(MedPage Today) -- FDA approval marks first anti-CD22 drug for treating the rare disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2018 Category: Hematology Source Type: news

FDA approves AstraZeneca's drug for rare form of blood cancer
The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA approves new kind of treatment for hairy cell leukemia
FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 13, 2018 Category: American Health Source Type: news

Novel Treatment Approved for'Hairy Cell' Leukemia
THURSDAY, Sept. 13, 2018 -- Lumoxiti injection has been approved to treat certain instances of relapsed or refractory " hairy cell " leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

Novel Treatment, Lumoxiti Injection, Approved for'Hairy Cell' Leukemia
THURSDAY, Sept. 13, 2018 -- Lumoxiti injection has been approved to treat certain instances of relapsed or refractory " hairy cell " leukemia (HCL), the U.S. Food and Drug Administration said Thursday. Lumoxiti (moxetumomab pasudotox-tdfk) is among a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 13, 2018 Category: General Medicine Source Type: news

Oral Contraceptive Use Link to Childhood Leukemia Oral Contraceptive Use Link to Childhood Leukemia
Maternal use of combined estrogen/progestin oral contraception near or during pregnancy was significantly associated with an increased risk for non-lymphoid-type leukemia in offspring.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Scientists Are Developing New Ways to Treat Disease With Cells, Not Drugs
When Nichelle Obar learned she was pregnant with her second child last year, she never expected that her pregnancy, or her baby, would make history. But when the 40-year-old food-and-beverage coordinator from Hawaii and her fiancé Christopher Constantino went to their 18-week ultrasound, they learned something was wrong. The heart was larger than it should have been, and there was evidence that fluid was starting to build up around the organ as well. Both were signs that the fetus was working extra hard to pump blood to its fast-growing body and that its heart was starting to fail. Obar’s doctor knew what coul...
Source: TIME: Health - September 13, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Innovation Health medicine Source Type: news